Table 1.
Characteristics of the 4509 Prostate Cancer Prevention Trial finasteride arm participants used for the analysis
| Characteristic | Biopsy Negative (n = 3827) |
Biopsy Positive (n = 682) |
|---|---|---|
| Age (y) | ||
| Mean (SD) | 69.7 (5.5) | 69.9 (5.9) |
| Range | 56-92 | 56-89 |
| Race n (%)* | ||
| White | 3648 (95.4) | 640 (93.8) |
| African American | 129 (3.4) | 37 (5.4) |
| Other | 49 (1.3) | 5 (0.7) |
| Previous biopsy n (%) | ||
| Never | 3326 (86.9) | 574 (84.2) |
| At least 1 | 501 (13.1) | 108 (15.8) |
| DRE, n (%)* | ||
| Normal | 3509 (91.7) | 536 (78.6) |
| Abnormal | 318 (8.3) | 146 (21.4) |
| Family history, n (%)* | ||
| No | 3248 (84.9) | 536 (78.6) |
| Yes | 579 (15.1) | 146 (21.4) |
| PSA (ng/mL)* | ||
| Mean (SD) | 0.7 (0.6) | 1.5 (1.4) |
| Range | 0.3-8.9 | 0.3-9.6 |
| TRUS volume (mL) | ||
| Mean (SD) | 27.0 (11.6) | 27.1 (14.4) |
| Range | 10-155.1 | 10.3-239 |
| Unknown n (%) | 437 (11.4) | 111 (16.3) |
| No. of biopsy cores (%)* | ||
| 1-5 | 25 (0.7) | 12 (1.8) |
| 6 | 3105 (81.1) | 490 (71.9) |
| 7-10 | 491 (12.8) | 112 (16.4) |
| 11-17 | 171 (4.5) | 39 (5.7) |
| Unknown | 35 (0.9) | 29 (4.3) |
| AUASS | ||
| Mean (SD) | 7.4 (5.4) | 7.3 (5.4) |
| Range | 0-32 | 0-31 |
| AUASS, n (%) | ||
| 0-9 | 2722 (71.1) | 492 (72.1) |
| 10-19 | 978 (25.6) | 166 (24.3) |
| 20-29 | 123 (3.2) | 23 (3.4) |
| 30-35 | 4 (0.1) | 1 (0.2) |
| Reason for biopsy (%)* | ||
| Interim (or for cause) | 494 (12.9) | 328 (48.1) |
| End-of-study | 3331 (87.1) | 354 (51.9) |
| Gleason grade (%) | ||
| ≤4 | – | 16 (2.4) |
| 5 | – | 53 (7.8) |
| 6 | – | 347 (50.9) |
| 7 | – | 179 (26.3) |
| ≥8 | – | 78 (11.4) |
| Unknown | – | 9 (1.3) |
AUASS, American Urological Association symptom score; DRE, digital rectal examination; PSA, prostate-specific antigen; SD, standard deviation; TRUS, transrectal ultrasound.
*
P value <.05 for difference between biopsy negative and positive.